

**VYEPTI® (eptinezumab-jjmr) ENROLLMENT FORM**

**1 PATIENT INFORMATION**

*(Please complete the following information)*

Patient Name (First, MI, Last): \_\_\_\_\_ DOB: \_\_\_\_\_ Gender: Male Female  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 Patient Phone Number: \_\_\_\_\_

**2 PATIENT INSURANCE INFORMATION**

**\*\*Please provide a copy of patient's MEDICAL and PRESCRIPTION cards\*\***

Primary Insurance Name: \_\_\_\_\_ Insurance Phone Number: \_\_\_\_\_  
 Primary Insurance ID: \_\_\_\_\_ Policyholder Name: \_\_\_\_\_

**3 MEDICAL ASSESSMENT**

**\*\*Please fax clinical documentation to pharmacy along with referral form.\*\***

Patient Height: \_\_\_\_\_ Patient Weight: \_\_\_\_\_ Allergies: \_\_\_\_\_  
 Diagnosis (ICD-10 Code): \_\_\_\_\_ Date Migraines started: \_\_\_\_\_ Number of headache days per month: \_\_\_\_\_

**Previous Acute Migraine Medication (last 3 months):**

Name of drug and dose	Duration of therapy	Outcome (effective, suboptimal, intolerant, failed)	Discontinued (Y/N) - Reason?
_____	_____	_____	_____
_____	_____	_____	_____
_____	_____	_____	_____

**Previous Prophylactic Migraine Medication (last 3 months):**

Name of drug and dose	Duration of therapy	Outcome (effective, suboptimal, intolerant, failed)	Discontinued (Y/N) - Reason?
_____	_____	_____	_____
_____	_____	_____	_____
_____	_____	_____	_____

**4 PRESCRIBER INFORMATION**

Practice Name: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_ Specialty: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Practice Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 Office Contact: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_ Email: \_\_\_\_\_

**5 SITE OF INFUSION**

**Please choose one:** Office Infusion Clinic Home

*If Infusion Clinic, please fill out below:*

Infusion Clinic Name: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 Infusion Clinic Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Email: \_\_\_\_\_

## 6 VYEPTI PRESCRIBING INFORMATION

### VYEPTI PRESCRIPTION

**Drug:** VYEPTI 100-mg/mL single-use vial | **SIG:** Infuse \_\_\_\_\_ mg over 30 min once every 3 months | **Qty:** \_\_\_\_\_ (vials) \_\_\_\_\_ Refills:

(Recommended dose is 100mg IV every 3 months. Some patients may benefit from Vyepti 300mg IV every 3 months. Supplied as Vypeti 100mg/ml - 1 ml vial)

**HOME INFUSION/NURSING ORDERS** (please check box if patient is infusing in the home)

- **Skilled Nursing Visit: As needed for IV access, drug administration and clinical monitoring.**
- **Provide necessary infusion and flush supplies (e.g. tubing).**
- **Infusion instructions:**
  - Use 10ml NS flush to establish line patency
  - Dilute in 100ml 0.9% Sodium Chloride Inj, USP.
  - Use an infusion set with 0.2 micron or 0.22 micron in-line or add-on sterile filter.
  - After infusion, flush IV line with 20ml of 0.9% NaCl.

### INFUSION REACTION MANAGEMENT ORDERS (complete these items as appropriate.)

1. If infusion reaction occurs **STOP drug infusion and start 0.9% saline 250ml- administer at 50ml/h once infusion stops**

2. **CALL PRESCRIBER at:** \_\_\_\_\_

3. **ADMINISTER EMERGENCY MEDS PER PHYSICIAN ORDERS** Quantity: 90 days Refills: 1 year

- Diphenhydramine \_\_\_\_\_ mg/ml IV push over 2 to 5 minutes for mild to moderate Infusion Reaction**
- Epinephrine 0.3mg IM injection for severe anaphylaxis. If severe symptoms persist, may repeat Epinephrine IM in 20 minutes, if needed. Call 911.**

## 7 PHYSICIAN SIGNATURE (Required)

X

PRODUCT SUBSTITUTION PERMITTED

Date of Signature

X

DISPENSE AS WRITTEN

Date of Signature

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.

